Replies to post #127359 on Biotech Values

[biomaven0]

NVS expects Gleevec generics to launch in the US market when the 5521184 composition-of-matter patent expires in Jul 2015.

I assume they are just being conservative in their forecasting here? Novartis do have the listed formulation patents going through 2019 - Sun will either have to show non-infringement, overturn them, or settle.

Peter